Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Medical Oncology
Erschienen in: Medical Oncology 1/2024

01.01.2024 | Review Article

Emerging treatment approaches for triple-negative breast cancer

verfasst von: Maurizio Capuozzo, Venere Celotto, Mariachiara Santorsola, Antonio Fabozzi, Loris Landi, Francesco Ferrara, Assunta Borzacchiello, Vincenza Granata, Francesco Sabbatino, Giovanni Savarese, Marco Cascella, Francesco Perri, Alessandro Ottaiano

Erschienen in: Medical Oncology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Approximately, 15% of global breast cancer cases are diagnosed as triple-negative breast cancer (TNBC), identified as the most aggressive subtype due to the simultaneous absence of estrogen receptor, progesterone receptor, and HER2. This characteristic renders TNBC highly aggressive and challenging to treat, as it excludes the use of effective drugs such as hormone therapy and anti-HER2 agents. In this review, we explore standard therapies and recent emerging approaches for TNBC, including PARP inhibitors, immune checkpoint inhibitors, PI3K/AKT pathway inhibitors, and cytotoxin-conjugated antibodies. The mechanism of action of these drugs and their utilization in clinical practice is explained in a pragmatic and prospective manner, contextualized within the current landscape of standard therapies for this pathology. These advancements present a promising frontier for tailored interventions with the potential to significantly improve outcomes for TNBC patients. Interestingly, while TNBC poses a complex challenge, it also serves as a paradigm and an opportunity for translational research and innovative therapies in the field of oncology.
Literatur
1.
Neophytou C, Boutsikos P, Papageorgis P. Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis. Front Oncol. 2018;8:31.PubMedCentralCrossRef
2.
Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9:S73–81.PubMedPubMedCentralCrossRef
3.
Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2021;72:136–45.PubMedCrossRef
4.
Petrucelli N, Daly MB, Pal T, BRCA1-and BRCA2-associated hereditary breast and ovarian cancer. 2022
5.
Vishnubalaji R, Alajez NM. Single-cell transcriptome analysis revealed heterogeneity and identified novel therapeutic targets for breast cancer subtypes. Cells. 2023;12:1182.PubMedPubMedCentralCrossRef
6.
Akhouayri L, Ostano P, Mello-Grand M, Gregnanin I, Crivelli F, Laurora S, et al. Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles. Hum Genomics. 2022;16:1–17.CrossRef
7.
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016;11: e0157368.PubMedPubMedCentralCrossRef
8.
Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19:5533–40.CrossRef
9.
Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688–98.PubMedCrossRef
10.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121:2750–67.PubMedPubMedCentralCrossRef
11.
Yu K-D, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, et al. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res. 2013;19:2723–33.PubMedCentralCrossRef
12.
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:1–18.CrossRef
13.
Staiger C, Cadot S, Györffy B, Wessels LF, Klau GW. Current composite-feature classification methods do not outperform simple single-genes classifiers in breast cancer prognosis. Front Genet. 2013;4:289.PubMedPubMedCentralCrossRef
14.
Xu Y, Xu Q, Yang L, Ye X, Liu F, Wu F, et al. Identification and validation of a blood-based 18-gene expression signature in colorectal cancer. Clin Cancer Res. 2013;19:3039–49.CrossRef
15.
Sabatier R, Diéras V, Pivot X, Brain E, Roche H, Extra J-M, et al. Safety results and analysis of eribulin efficacy according to previous microtubules-inhibitors sensitivity in the French prospective expanded access program for heavily pre-treated metastatic breast cancer. Cancer Res Treat. 2018;50:1226–37.PubMedCrossRef
16.
Watanabe G, Chiba N, Nomizu T, Furuta A, Sato K, Miyashita M, et al. Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis. Cancer Sci. 2018;109:2027–35.PubMedPubMedCentralCrossRef
17.
Kang SY, Kim YS, Kim Z, Kim HY, Kim HJ, Park S, et al. Breast cancer statistics in Korea in 2017: data from a breast cancer registry. J Breast Cancer. 2020;23:115.PubMedPubMedCentralCrossRef
18.
Larsen NB, Rasmussen M, Rasmussen LJ. Nuclear and mitochondrial DNA repair: similar pathways? Mitochondrion. 2005;5:89–108.PubMedCrossRef
19.
Perkhofer L, Gout J, Roger E, de Almeida FK, Simões CB, Wiesmüller L, Seufferlein T, Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut. 2021;70(3):606–17.PubMedCrossRef
20.
Azim HA, Loutfy SA, Azim HA Jr, Kamal NS, Abdel Fattah NF, Elberry MH, Abdelaziz MR, Abdelsalam M, Aziz M, Shohdy KS, Kassem L. The landscape of BRCA mutations among egyptian women with breast cancer. Oncol Ther. 2023;15:1–8.
21.
Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer. 2021;146:30–47.PubMedCrossRef
22.
Kwong A, Chen J, Shin VY, Ho JC, Law FB, Au CH, Chan TL, Ma ES, Ford JM. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. Cancer Genet. 2015;208(9):448–54.PubMedCrossRef
23.
Sullivan MR, Bernstein KA. RAD-ical new insights into RAD51 regulation. Genes (Basel). 2018;9(12):629.PubMedCrossRef
24.
Qin Z, Li J, Tam B, Sinha S, Zhao B, Bhaskaran SP, Huang T, Wu X, Chian JS, Guo M, Kou SH, Lei H, Zhang L, Wang X, Lagniton PNP, Xiao F, Jiang X, Wang SM. Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population. Int J Cancer. 2023;152(6):1159–73.PubMedCrossRef
25.
Kwong A, Ho CYS, Shin VY, Au CH, Luk WP, Fung LH, Chan TL, Chan KKL, Ngan HYS, Ma ESK. Germline mutations in Chinese ovarian cancer with or without breast cancer. Mol Genet Genomic Med. 2022;10(7): e1940.PubMedPubMedCentralCrossRef
26.
Caleca L, Radice P. Refinement of the assignment to the ACMG/AMP BS3 and PS3 criteria of eight BRCA1 variants of uncertain significance by integrating available functional data with protein interaction assays. Front Oncol. 2023;13:1146604.PubMedPubMedCentralCrossRef
27.
Cetin B, Wabl CA, Gumusay O. The DNA damaging revolution. Crit Rev Oncol Hematol. 2020;156: 103117.PubMedCrossRef
28.
Ford D, Easton D, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676–89.PubMedPubMedCentralCrossRef
29.
Rummel S, Varner E, Shriver CD, Ellsworth RE. Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat. 2013;137:119–25.CrossRef
30.
Ellsworth DL, Turner CE, Ellsworth RE. A review of the hereditary component of triple negative breast cancer: High-and moderate-penetrance breast cancer genes, low-penetrance loci, and the role of nontraditional genetic elements. J Oncol. 2019;25:78–96.
31.
Melki R, Melloul M, Aissaoui S, El-Harroudi T. Increased prevalence of the founder BRCA1 c. 5309G> T and recurrent BRCA2 c. 1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling. BMC Cancer. 2023;23:339.PubMedPubMedCentralCrossRef
32.
Abdallah N, Purrington KS, Tatineni S, Assad H, Petrucelli N, Simon MS. Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center. Cancer Causes Control. 2023;34:141–9.PubMedCrossRef
33.
Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manage Res. 2019;15:2321–37.CrossRef
34.
Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer. 2022;15:15–24.
35.
Wang J, Zhao H, Ye L, Li J, Zhang H, Zhang C, et al., Diagnostic and prognostic nomograms for lung metastasis in triple-negative breast cancer. Comput Math Methods Med. 2022
36.
Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, et al. Inclusion of platinum agents in neoadjuvant chemotherapy regimens for triple-negative breast cancer patients: development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Medical Oncology (AIOM). Cancers. 2019;11:1137.PubMedPubMedCentralCrossRef
37.
Al-Showimi M, Al-Yousef N, Alharbi W, Alkhezayem S, Almalik O, Alhusaini H, et al. MicroRNA-126 expression in the peripheral white blood cells of patients with breast and ovarian cancer is a potential biomarker for the early prediction of cancer risk in the carriers of methylated BRCA1. Oncol Lett. 2022;24:1–9.CrossRef
38.
Biswas T, Efird JT, Prasad S, Jindal C, Walker PR. The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer. Oncotarget. 2017;8: 112712.PubMedPubMedCentralCrossRef
39.
Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28:375–9.PubMedCrossRef
40.
Torrisi R, Zuradelli M, Agostinetto E, Masci G, Losurdo A, De Sanctis R, et al. Platinum salts in the treatment of BRCA-associated breast cancer: a true targeted chemotherapy? Crit Rev Oncol Hematol. 2019;135:66–75.PubMedCrossRef
41.
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13.PubMedCrossRef
42.
Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15:747–56.CrossRef
43.
Poggio F, Bruzzone M, Ceppi M, Pondé N, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29:1497–508.PubMedCrossRef
44.
Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24:628–37.PubMedPubMedCentralCrossRef
45.
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro M, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623–49.CrossRef
46.
47.
Mateo J, Lord C, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30:1437–47.PubMedPubMedCentralCrossRef
48.
Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.PubMedCrossRef
49.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.PubMedPubMedCentralCrossRef
50.
Rugo HS, Olopade OI, DeMichele A, Yau C, van Veer LJ, Buxton MB, et al. Adaptive randomization of veliparib–carboplatin treatment in breast cancer. N Engl J Med. 2016;375:23–34.PubMedCentralCrossRef
51.
Geyer CE, O'Shaughnessy J, Untch M, Sikov W, Rugo HS, McKee MD, et al. Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). In: American Society of Clinical Oncology; 2017
52.
Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020;38:388.PubMedCrossRef
53.
Fasching P, Link T, Hauke J, Seither F, Jackisch C, Klare P, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 2021;32:49–57.PubMedCrossRef
54.
Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, et al. Cisplatin+/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. NPJ Breast Cancer. 2021;7:29.PubMedPubMedCentralCrossRef
55.
Tutt A, Stephens C, Frewer P, Pierce A, Rhee J, So K, et al. VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes. In.: American Society of Clinical Oncology; 2018.
56.
Kirova YM, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga J-Y, et al. Radioparp: A phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC with residual disease—Preliminary results. In.: American Society of Clinical Oncology; 2020.
57.
Wang X, Collet L, Rediti M, Debien V, De Caluwé A, Venet D, et al. Predictive biomarkers for response to immunotherapy in triple negative breast cancer: promises and challenges. J Clin Med. 2023;12:953.PubMedPubMedCentralCrossRef
58.
Sadreddini S, Baradaran B, Aghebati-Maleki A, Sadreddini S, Shanehbandi D, Fotouhi A, et al. Immune checkpoint blockade opens a new way to cancer immunotherapy. J Cell Physiol. 2019;234:8541–9.PubMedCrossRef
59.
Kuske M, Haist M, Jung T, Grabbe S, Bros M. Immunomodulatory properties of immune checkpoint inhibitors-more than boosting t-cell responses? Cancers (Basel). 2022;14(7):1710.PubMedCrossRef
60.
Kumar S, Singh SK, Srivastava P, Suresh S, Rana B, Rana A. Interplay between MAP kinases and tumor microenvironment: opportunity for immunotherapy in pancreatic cancer. Adv Cancer Res. 2023;159:113–43.PubMedCrossRef
61.
Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali H, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015; 6 (7): 5449–64. Largest retrospective study analysing the mRNA expression of PD-L1 in.5.
62.
Ni Y, Tsang JY, Shao Y, Poon IK, Tam F, Shea K-H, et al. Combining analysis of tumor-infiltrating lymphocytes (TIL) and PD-L1 refined the prognostication of breast cancer subtypes. Oncologist. 2022;27:e313–27.PubMedCentralCrossRef
63.
Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, et al. A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer. Oncologist. 2021;26:99-e217.CrossRef
64.
Sood R, Kumar S, Laroiya I, Khare S, Das A, Singh G, et al. Assessment of PD-L1 expression and tumor-infiltrating lymphocytes (TILs) across molecular subtypes of triple-negative breast cancer. Breast J. 2020;26:2424–7.PubMedCrossRef
65.
Li M, Li A, Zhou S, Xu Y, Xiao Y, Bi R, et al. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer. 2018;18:1–9.
66.
Carter JM, Polley MYC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, et al. Characteristics and spatially defined immune (micro) landscapes of early-stage PD-L1-positive Triple-negative Breast Cancer. Clin Cancer Res. 2021;27:5628–37.PubMedCentralCrossRef
67.
Bertucci F, Gonçalves A. Immunotherapy in breast cancer: the emerging role of PD-1 and PD-L1. Curr Oncol Rep. 2017;19:1–11.CrossRef
68.
Fabozzi A, Della Sala F, di Gennaro M, Solimando N, Pagliuca M, Borzacchiello A. Polymer based nanoparticles for biomedical applications by microfluidic techniques: from design to biological evaluation. Polym Chem. 2021;12:6667–87. https://​doi.​org/​10.​1039/​d1py01077h.CrossRef
69.
Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 2019;17:1–9.CrossRef
70.
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44–59.PubMedCrossRef
71.
Adams S, Schmid P, Rugo H, Winer E, Loirat D, Awada A, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:397–404.PubMedCrossRef
72.
Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34:2460.PubMedCentralCrossRef
73.
Gianni L, Huang C-S, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33:534–43.CrossRef
74.
Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, et al. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130. Ann Oncol. 2019;30:v858–9.CrossRef
75.
Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, et al. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Ann Oncol. 2018;29:2121–8.CrossRef
76.
Bianchini G, Huang C, Egle D, Bermejo B, Zamagni C, Thill M, et al. LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. Ann Oncol. 2020;31:S1145–6.CrossRef
77.
Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021;12:6276.PubMedPubMedCentralCrossRef
78.
Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, et al. (2016) Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Sci Transl Med. 2016;8:334.CrossRef
79.
Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2:1354–60.PubMedCrossRef
80.
Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228–41.PubMedCrossRef
81.
Bareche Y, Buisseret L, Gruosso T, Girard E, Venet D, Dupont F, et al. Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach. JNCI. 2020;112:708–19.CrossRef
82.
Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, Criscitiello C, et al. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Eur J Cancer. 2019;118:41–8.PubMedCrossRef
83.
Gao ZH, Li CX, Liu M, Jiang JY. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer. 2020;20:1–14.
84.
Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.PubMedCrossRef
85.
Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959.PubMedPubMedCentralCrossRef
86.
Manzo E, Fioretto L, Gallo C, Ziaco M, Nuzzo G, D’Ippolito G, et al. Preparation, supramolecular aggregation and immunological activity of the bona fide vaccine adjuvant sulfavant s. Mar Drugs. 2020;18:451.PubMedPubMedCentralCrossRef
87.
Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37:559.PubMedPubMedCentralCrossRef
88.
Park J, Jonas S, Bataillon G, Criscitiello C, Salgado R, Loi S, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann Oncol. 2019;30:1941–9.PubMedCrossRef
89.
Loi S, Michiels S, Adams S, Loibl S, Budczies J, Denkert C, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021;32:1236–44.PubMedCrossRef
90.
Sasaki R, Horimoto Y, Yanai Y, Kurisaki-Arakawa A, Arakawa A, Nakai K, et al. Molecular characteristics of lymphocyte-predominant triple-negative breast cancer. Anticancer Res. 2021;41:2133–40.PubMedCrossRef
91.
Criscitiello C, Bayar M, Curigliano G, Symmans F, Desmedt C, Bonnefoi H, et al. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Ann Oncol. 2018;29:162–9.PubMedCrossRef
92.
Fabozzi A, Della Sala F, di Gennaro M, Borzacchiello A. Synthesis of hyaluronic acid core–shell nanoparticles via simple microfluidic-assisted nanoprecipitation method for active tumor targeting. New J Chem. 2022;46:19763–72.CrossRef
93.
Loi S, Adams S, Schmid P, Cortés J, Cescon D, Winer E, et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086. Ann Oncol. 2017;28: v608.CrossRef
94.
Loi S, Schmid P, Aktan G, Karantza V, Salgado R. Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+ chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial. Ann Oncol. 2019;30:32.CrossRef
95.
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio I, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220.PubMedCrossRef
96.
Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic markers in triple-negative breast cancer. Clin Breast Cancer. 2018;18:e841–50.PubMedCrossRef
97.
Jin J, He J, Li X, Ni X, Jin X. The role of ubiquitination and deubiquitination in PI3K/AKT/mTOR pathway: a potential target for cancer therapy. Gene. 2023;889: 147807.PubMedCrossRef
98.
99.
Álvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It’s all about diversity. Semin Cancer Biol. 2019;59:66–79.CrossRef
100.
Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G, et al. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res. 2014;16:1–16.CrossRef
101.
Martín M, Chan A, Dirix L, O’Shaughnessy J, Hegg R, Manikhas A, et al. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2–advanced breast cancer (BELLE-4). Ann Oncol. 2017;28:313–20.PubMedCrossRef
102.
Kim S-B, Dent R, Im S-A, Espié M, Blau S, Tan AR, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18:1360–72.PubMedPubMedCentralCrossRef
103.
Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol. 2020;38:423–33.PubMedCrossRef
104.
Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, et al. TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26:2111–23.PubMedCrossRef
105.
Sussman D, Smith LM, Anderson ME, Duniho S, Hunter JH, Kostner H, et al. SGN–LIV1A: a novel antibody–drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014;13:2991–3000.PubMedCrossRef
106.
Saravanan R, Balasubramanian V, Swaroop Balamurugan SS, Ezhil I, Afnaan Z, John J, et al. Zinc transporter LIV1: A promising cell surface target for triple negative breast cancer. J Cell Physiol. 2022;237:4132–56.PubMedCrossRef
107.
Fabozzi A, Della Sala F, di Gennaro M, Barretta M, Longobardo G, Solimando N, et al. Design of functional nanoparticles by microfluidic platforms as advanced drug delivery systems for cancer therapy. Lab Chip. 2023;23:1389–409.PubMedCrossRef
108.
Vessella G, Casillo A, Fabozzi A, Traboni S, Iadonisi A, Corsaro MM, et al. Synthesis of the tetrasaccharide repeating unit of the cryoprotectant capsular polysaccharide from Colwellia psychrerythraea 34H. Org Biomol Chem. 2019;17:3129–40.PubMedCrossRef
109.
Shi D, Li Y, Liang X, Chen L. Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Front Oncol. 2023;13:1162360.PubMedCentralCrossRef
110.
Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989.PubMedPubMedCentralCrossRef
111.
Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. The Breast. 2022;66:169–77.PubMedPubMedCentralCrossRef
112.
113.
McGuinness JE, Kalinsky K. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. Expert Opin Biol Ther. 2021;21:903–13.CrossRef
114.
Fabozzi A, Barretta M, Valente T, Borzacchiello A. Preparation and optimization of hyaluronic acid decorated irinotecan-loaded poly (lactic-co-glycolic acid) nanoparticles by microfluidics for cancer therapy applications. Colloids Surf A. 2023;15:131790.CrossRef
115.
Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, et al. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35:2141.PubMedPubMedCentralCrossRef
116.
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–51.PubMedCrossRef
117.
Bardia A, Tolaney S, Loirat D, Punie K, Oliveira M, Rugo H, et al. LBA17 ASCENT: a randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2020;31:S1149–50.CrossRef
118.
Rose AA, Grosset A-A, Dong Z, Russo C, MacDonald PA, Bertos NR, et al. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res. 2010;16:2147–56.PubMedCrossRef
119.
120.
121.
122.
123.
124.
125.
126.
Doha ZO, Wang X, Calistri NL, Eng J, Daniel CJ, Ternes L, Kim EN, Pelz C, Munks M, Betts C, Kwon S, Bucher E, Li X, Waugh T, Tatarova Z, Blumberg D, Ko A, Kirchberger N, Pietenpol JA, Sanders ME, Langer EM, Dai MS, Mills G, Chin K, Chang YH, Coussens LM, Gray JW, Heiser LM, Sears RC. MYC deregulation and PTEN loss model tumor and stromal heterogeneity of aggressive triple-negative breast cancer. Nat Commun. 2023;14(1):5665. https://​doi.​org/​10.​1038/​s41467-023-40841-6.CrossRefPubMedPubMedCentral
127.
Houthuijzen JM, de Bruijn R, van der Burg E, Drenth AP, Wientjens E, Filipovic T, Bullock E, Brambillasca CS, Pulver EM, Nieuwland M, de Rink I, van Diepen F, Klarenbeek S, Kerkhoven R, Brunton VG, Scheele CLGJ, Boelens MC, Jonkers J. CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer. Nat Commun. 2023;14(1):183. https://​doi.​org/​10.​1038/​s41467-023-35793-w.CrossRefPubMedPubMedCentral
Metadaten
Titel
Emerging treatment approaches for triple-negative breast cancer
verfasst von
Maurizio Capuozzo
Venere Celotto
Mariachiara Santorsola
Antonio Fabozzi
Loris Landi
Francesco Ferrara
Assunta Borzacchiello
Vincenza Granata
Francesco Sabbatino
Giovanni Savarese
Marco Cascella
Francesco Perri
Alessandro Ottaiano
Publikationsdatum
01.01.2024
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2024
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-023-02257-6

Weitere Artikel der Ausgabe 1/2024

Medical Oncology 1/2024 Zur Ausgabe

Original Paper

Chitosan-encapsulated naringenin promotes ROS mediated through the activation of executioner caspase-3

Original Paper

USP10 promotes migration and cisplatin resistance in esophageal squamous cell carcinoma cells

Review Article

Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment

Original Paper

Ammonia scavenger and glutamine synthetase inhibitors cocktail in targeting mTOR/β-catenin and MMP-14 for nitrogen homeostasis and liver cancer

Review Article

Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy

Original Paper

Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise